IMC-1 Fibromyalgia Treatment Reduces Pain and Symptoms

Author: Innovative Med Concepts, LLC
Published: 2014/11/20 - Updated: 2020/12/13
Contents: Summary - Introduction - Main - Related

Synopsis: IMC-1 oral medication proves highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial. IMC-1 is a novel combination oral medicine designed to treat HSV-1, a condition that may be one of the underlying causes of fibromyalgia syndrome. Fibromyalgia is a multi-symptom disorder involving widespread pain, fatigue, headaches, sleep problems, mood changes and inability to concentrate.

Introduction

Detailed results of the randomized, double-blinded, placebo-controlled Phase II study, known as PRID-201, were presented today at the 2014 American College of Rheumatology annual meeting in Boston by William L. Pridgen, M.D., FACS, founder and CEO of Innovative Med Concepts.

Main Digest

According to Daniel J. Clauw, M.D., director of the Chronic Pain & Fatigue Research Center at the University of Michigan (Ann Arbor), commenting on the PRID-201 results, "IMC-1 shows promise as a potentially new treatment for the millions of people who suffer from this debilitating condition."

IMC-1 is a novel combination oral medicine designed to treat HSV-1, a condition that may be one of the underlying causes of fibromyalgia syndrome. IMC-1 combines the anti-herpes virus nucleoside analog famciclovir with anti-herpes virus activity exhibited by the COX-2 inhibitor celecoxib.

Fibromyalgia is a multi-symptom disorder involving widespread pain, fatigue, headaches, sleep problems, mood changes and inability to concentrate. Its causes are unknown. According to the National Fibromyalgia Association, an estimated 3-6 percent of people worldwide suffer from the condition - 10 million people in the United States alone.

The 16-week study evaluated the efficacy and safety of IMC-1, a fixed-dose-combination of famciclovir and celecoxib. 143 FM patients were recruited at 12 U.S. clinics. Patients received either a combination treatment of IMC-1 or a matching placebo.

According to Dr. Pridgen, chronic tissue-resident herpes virus may be an underlying cause of fibromyalgia. IMC-1 represents a novel treatment by combining an anti-herpes virus nucleoside analog with the anti-herpes virus activity exhibited by a COX-2 inhibitor.

"Many herpes viruses are known to significantly upregulate COX enzymes in the body, which in turn are important for efficient viral replication," Pridgen said. "In theory, physical or emotional stress in patients can reactivate the virus and result in perpetuation of the symptoms of fibromyalgia. Effectively suppressing latent viruses may significantly improve the pain and related symptoms of FM."

The PRID-201 clinical study tested this hypothesis using the IMC-1 fixed-dose-combination. Patients in the trial rated their pain over the course of the study using a 0-10 numeric rating scale, with the study's primary endpoint being the reduction in average pain from baseline to week 16. Pain measured on both a 24-hour and seven-day recall basis met statistical significance, with the seven-day recall data achieving high statistical significance (p=0.001). Other therapeutic domains studied that showed statistical significance were Patient Global Impression (PGIC), all three Revised Fibromyalgia Impact Questionnaire (FIQ-R) domains, 30% and 50% Pain reduction responder analysis and the NIH PROMIS fatigue instrument.

Noteworthy Results from PRID-201

"Compared to placebo, the relatively high completion rate, improved pain scores and the low rate of discontinuation because of adverse events are consistent with a well-tolerated and effective therapy," Dr. Clauw said.

Innovative Med Concepts, LLC, is a biotech company developing novel treatments for fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), irritable bowel syndrome and other related conditions. On the Web: innovativemedconcepts.com

Attribution/Source(s):

This quality-reviewed publication titled IMC-1 Fibromyalgia Treatment Reduces Pain and Symptoms was selected for publishing by Disabled World's editors due to its relevance to the disability community. While the content may have been edited for style, clarity, or brevity, it was originally authored by Innovative Med Concepts, LLC and published 2014/11/20 (Edit Update: 2020/12/13). For further details or clarifications, you can contact Innovative Med Concepts, LLC directly at innovativemedconcepts.com Disabled World does not provide any warranties or endorsements related to this article.

Related Publications

Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide news and information to people with disabilities, seniors, their family and carers. You can connect with us on social media such as X.com and Facebook.

Cite This Page (APA): Innovative Med Concepts, LLC. (2014, November 20). IMC-1 Fibromyalgia Treatment Reduces Pain and Symptoms. Disabled World. Retrieved May 26, 2024 from www.disabled-world.com/medical/clinical-trials/imc-1.php

Permalink: <a href="https://www.disabled-world.com/medical/clinical-trials/imc-1.php">IMC-1 Fibromyalgia Treatment Reduces Pain and Symptoms</a>: IMC-1 oral medication proves highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.